Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001241331 | SCV001414344 | likely benign | Hereditary insensitivity to pain with anhidrosis | 2024-01-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001569507 | SCV001793599 | uncertain significance | not provided | 2021-02-22 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; In silico analysis, which includes splice predictors and evolutionary conservation, suggests this variant may impact gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown. |
Ambry Genetics | RCV002379925 | SCV002692499 | uncertain significance | Inborn genetic diseases | 2019-11-07 | criteria provided, single submitter | clinical testing | The p.N434K variant (also known as c.1302C>G), located in coding exon 10 of the NTRK1 gene, results from a C to G substitution at nucleotide position 1302. The asparagine at codon 434 is replaced by lysine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001241331 | SCV002086563 | uncertain significance | Hereditary insensitivity to pain with anhidrosis | 2020-01-21 | no assertion criteria provided | clinical testing |